HTSU.F Stock Overview
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.56 |
| 52 Week High | JP¥36.00 |
| 52 Week Low | JP¥23.70 |
| Beta | 0.40 |
| 1 Month Change | -4.72% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -59.74% |
| 5 Year Change | n/a |
| Change since IPO | -9.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| HTSU.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.6% | -0.6% | 1.0% |
| 1Y | n/a | 10.6% | 21.9% |
Return vs Industry: Insufficient data to determine how HTSU.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HTSU.F performed against the US Market.
Price Volatility
| HTSU.F volatility | |
|---|---|
| HTSU.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HTSU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HTSU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1847 | 2,769 | Kazuhide Nakatomi | www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
| HTSU.F fundamental statistics | |
|---|---|
| Market cap | US$1.81b |
| Earnings (TTM) | US$89.82m |
| Revenue (TTM) | US$911.17m |
20.1x
P/E Ratio2.0x
P/S RatioIs HTSU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTSU.F income statement (TTM) | |
|---|---|
| Revenue | JP¥141.71b |
| Cost of Revenue | JP¥62.74b |
| Gross Profit | JP¥78.97b |
| Other Expenses | JP¥65.00b |
| Earnings | JP¥13.97b |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 184.43 |
| Gross Margin | 55.73% |
| Net Profit Margin | 9.86% |
| Debt/Equity Ratio | 0.4% |
How did HTSU.F perform over the long term?
See historical performance and comparison